[go: up one dir, main page]

GT201200247A - Formulaciones orales y sales lipofílicas de metilnaltrexona - Google Patents

Formulaciones orales y sales lipofílicas de metilnaltrexona

Info

Publication number
GT201200247A
GT201200247A GT201200247A GT201200247A GT201200247A GT 201200247 A GT201200247 A GT 201200247A GT 201200247 A GT201200247 A GT 201200247A GT 201200247 A GT201200247 A GT 201200247A GT 201200247 A GT201200247 A GT 201200247A
Authority
GT
Guatemala
Prior art keywords
methylntrexone
lipophylic
salts
oral formulations
formulations
Prior art date
Application number
GT201200247A
Other languages
English (en)
Inventor
Syed M Shah
Diorio Christopher Richard
Eric C Ehrnsperger
Meng Xu
Shareffi Kadum A Al
Cohen Jonathan Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200247(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200247A publication Critical patent/GT201200247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES QUE COMPRENDEN METILNALTREXONA O UNA SAL DE ÉSTOS Y COMPOSICIONES Y FORMULACIONES DE ÉSTA, PARA ADMINISTRACIÓN ORAL. EL USO DE ESTOS OPIOIDES ACTIVAN LOS RECEPTORES OPIOIDES LOCALIZADOS EN EL SISTEMA NERVIOSO CENTRAL PARA ALIVIAR EL DOLOR.
GT201200247A 2010-03-11 2012-08-23 Formulaciones orales y sales lipofílicas de metilnaltrexona GT201200247A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
GT201200247A true GT201200247A (es) 2013-09-11

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200247A GT201200247A (es) 2010-03-11 2012-08-23 Formulaciones orales y sales lipofílicas de metilnaltrexona

Country Status (32)

Country Link
US (8) US8524276B2 (es)
EP (2) EP3178472B1 (es)
JP (4) JP6143409B2 (es)
KR (2) KR101982482B1 (es)
CN (2) CN102918039B (es)
AR (1) AR080491A1 (es)
AU (1) AU2011224275B2 (es)
BR (1) BR112012022873B1 (es)
CA (1) CA2789798C (es)
CL (1) CL2012002192A1 (es)
CO (1) CO6630134A2 (es)
CR (1) CR20120476A (es)
EA (1) EA029096B1 (es)
EC (1) ECSP12012208A (es)
ES (1) ES2623926T3 (es)
GE (1) GEP201606550B (es)
GT (1) GT201200247A (es)
HU (1) HUE033133T2 (es)
IL (1) IL221452A (es)
MA (1) MA34146B1 (es)
MX (2) MX349145B (es)
MY (1) MY160727A (es)
NZ (3) NZ703564A (es)
PE (1) PE20130063A1 (es)
PH (1) PH12012501622A1 (es)
PL (2) PL2371357T3 (es)
SG (3) SG183133A1 (es)
TN (1) TN2012000392A1 (es)
TW (2) TWI589293B (es)
UA (2) UA123856C2 (es)
WO (1) WO2011112816A1 (es)
ZA (1) ZA201808498B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
MA34146B1 (fr) 2010-03-11 2013-04-03 Wyeth Llc Formulations oralles et sels lipophiles de methylnaltrexone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CN107249327A (zh) 2014-10-17 2017-10-13 萨利克斯药品公司 使用甲基纳曲酮减缓肿瘤进展
KR20210105381A (ko) * 2018-12-19 2021-08-26 프리울켐 에스.피.에이. 리팍시민 정제의 제조 방법 및 리팍시민 정제
AU2020268767B8 (en) * 2019-05-07 2025-08-07 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3177250A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
ES2141631T3 (es) 1997-02-14 2000-03-16 Goedecke Ag Estabilizacion del hidrocloruro de naloxon.
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
US20030065002A1 (en) * 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE60234183D1 (de) 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
SI1436012T1 (en) 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
DE60237388D1 (de) * 2001-11-29 2010-09-30 Schering Corp Verfahren zur herstellung von zusammensetzungen mit erhöhtem gehalt von salzen pharmazeutisch aktiver rotamere
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
MXPA05010821A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060009504A1 (en) 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
ES2392645T3 (es) 2004-09-30 2012-12-12 Becton,Dickinson And Company Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
MY156913A (en) * 2008-05-07 2016-04-15 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
MA34146B1 (fr) 2010-03-11 2013-04-03 Wyeth Llc Formulations oralles et sels lipophiles de methylnaltrexone
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
UA111717C2 (uk) 2016-06-10
MX349145B (es) 2017-07-14
CN102918039B (zh) 2017-06-09
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
PH12012501622A1 (en) 2012-11-05
TWI605814B (zh) 2017-11-21
MX368805B (es) 2019-10-17
CN107308125A (zh) 2017-11-03
AU2011224275A1 (en) 2012-08-23
US20200121673A1 (en) 2020-04-23
US8524276B2 (en) 2013-09-03
IL221452A (en) 2017-07-31
KR20130010900A (ko) 2013-01-29
ECSP12012208A (es) 2015-03-31
CN107308125B (zh) 2021-07-16
PE20130063A1 (es) 2013-02-11
CO6630134A2 (es) 2013-03-01
PL2371357T3 (pl) 2017-09-29
SG183133A1 (en) 2012-09-27
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
GEP201606550B (en) 2016-10-10
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
US20140249171A1 (en) 2014-09-04
US20130330407A1 (en) 2013-12-12
JP6429955B2 (ja) 2018-11-28
NZ702826A (en) 2016-08-26
KR101913102B1 (ko) 2018-10-31
NZ703564A (en) 2016-08-26
US10507206B2 (en) 2019-12-17
CA2789798C (en) 2020-09-22
CR20120476A (es) 2012-11-30
SG10201501821RA (en) 2015-05-28
SG10201606618PA (en) 2016-09-29
TW201622724A (zh) 2016-07-01
TN2012000392A1 (en) 2014-01-30
US20160206612A1 (en) 2016-07-21
EA201270741A1 (ru) 2013-02-28
WO2011112816A1 (en) 2011-09-15
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
UA123856C2 (uk) 2021-06-16
NZ601595A (en) 2015-01-30
EA029096B1 (ru) 2018-02-28
IL221452A0 (en) 2012-10-31
MY160727A (en) 2017-03-15
BR112012022873A2 (pt) 2016-08-30
BR112012022873B1 (pt) 2021-09-14
US20190314365A1 (en) 2019-10-17
EP2371357B1 (en) 2017-02-01
CN102918039A (zh) 2013-02-06
AR080491A1 (es) 2012-04-11
JP6143409B2 (ja) 2017-06-07
ES2623926T3 (es) 2017-07-12
JP6647368B2 (ja) 2020-02-14
JP2011190259A (ja) 2011-09-29
US20120070495A1 (en) 2012-03-22
JP2019034958A (ja) 2019-03-07
EP2371357A1 (en) 2011-10-05
MA34146B1 (fr) 2013-04-03
HUE033133T2 (en) 2017-11-28
JP2017206553A (ja) 2017-11-24
TW201141479A (en) 2011-12-01
US20190117645A1 (en) 2019-04-25
US10376505B2 (en) 2019-08-13
EP3178472B1 (en) 2021-10-27
MX2012009125A (es) 2012-09-07
US9314461B2 (en) 2016-04-19
EP3178472A1 (en) 2017-06-14
CL2012002192A1 (es) 2012-09-28
US10307417B2 (en) 2019-06-04
HK1245673A1 (zh) 2018-08-31
JP2016029054A (ja) 2016-03-03
US20190117646A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
GT201200247A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
GT200900292A (es) "inhibidores de cinasa p70 s6"
NI201500167A (es) Compuestos químicos
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
HN2010001647A (es) INHIBIDORES DE HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
CL2013000477A1 (es) Formulacion farmaceutica oral de liberacion inmediata que comprende nalbufina o una sal de la misma, y al menos, un soporte de granulacion hidrofilo, un aglutinante hidrofilo y un lubricante, util para el tratamiento del dolor y la dependencia a los opioides.
CL2013000866A1 (es) Sales cristalinas oxalato y fosfato del conjugado naloxolpolietilenglicol; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento del dolor.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112013012117A8 (pt) Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CR11601A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp
CL2012002823A1 (es) Composición farmacéutica para el tratamiento de la diabetes y los trastornos relacionados, que comprende un sensibilizador de insulina seleccionado entre pioglitazona y rosiglitazona, glimepirida y metmorfina; formulación farmacéutica oral que la comprende; kit para tratar diabetes tipo ii; y uso de dicha formulación para tratar diabetes.
CO6680604A2 (es) Forma cristalina de un compuesto 3-fenocimetilpirrolidina
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos